Other
Mark Santillan
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
50.0%
1 terminated/withdrawn out of 2 trials
Success Rate
50.0%
-36.6% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
N/A
1(100.0%)
1Total
N/A(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT03938129Completed
Improving Women's and Children's Health Via Biobanking and Electronic Registry
Role: lead
NCT03715530Not ApplicableTerminated
Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women
Role: lead
All 2 trials loaded